Évaluation d’une dosimétrie in vivo de transit utilisant l’imageur portal et comparaison avec les mesures par diodes

Royer, P.; Marchesi, V.; Rousseau, V.; Buchheit, I.; Peiffert, D.; Noël, Alain

doi:10.1016/j.canrad.2014.03.006

Cited by 7 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this perspective, transit dosimetry using amorphous silicon electronic portal imaging devices (EPID) appears to be an interesting alternative for several practical reasons (12) . Portal IVD is easy to use and requires neither additional setup time nor additional detectors.…”

Section: Introductionmentioning

confidence: 99%

EPID based in vivo dosimetry system: clinical experience and results

Celi

Costa

Wessels

et al. 2016

J Applied Clin Med Phys

View full text Add to dashboard Cite

Mandatory in several countries, in vivo dosimetry has been recognized as one of the next milestones in radiation oncology. Our department has implemented clinically an EPID based in vivo dosimetry system, EPIgray, by DOSISOFT S.A., since 2006. An analysis of the measurements per linac and energy over a two‐year period was performed, which included a more detailed examination per technique and treatment site over a six‐month period. A comparison of the treatment planning system doses and the doses estimated by EPIgray shows a mean of the differences of 1.9% (±5.2%) for the two‐year period. The 3D conformal treatment plans had a mean dose difference of 2.0% (±4.9%), while for intensity‐modulated radiotherapy and volumetric‐modulated arc therapy treatments the mean dose difference was −3.0 (±5.3%) and −2.5 (±5.2%), respectively. In addition, root cause analyses were conducted on the in vivo dosimetry measurements of two breast cancer treatment techniques, as well as prostate treatments with intensity‐modulated radiotherapy and volumetric‐modulated arc therapy. During the breast study, the dose differences of breast treatments in supine position were correlated to patient setup and EPID positioning errors. Based on these observations, an automatic image shift correction algorithm is developed by DOSIsoft S.A. The prostate study revealed that beams and arcs with out‐of‐tolerance in vivo dosimetry results tend to have more complex modulation and a lower exposure of the points of interest. The statistical studies indicate that in vivo dosimetry with EPIgray has been successfully implemented for classical and complex techniques in clinical routine at our institution. The additional breast and prostate studies exhibit the prospects of EPIgray as an easy supplementary quality assurance tool. The validation, the automatization, and the reduction of false‐positive results represent an important step toward adaptive radiotherapy with EPIgray.PACS number(s): 87.53.Bn, 87.55.Qr, 87.56.Fc, 87.57.uq

show abstract

Section: Introductionmentioning

confidence: 99%

EPID based in vivo dosimetry system: clinical experience and results

Celi

Costa

Wessels

et al. 2016

J Applied Clin Med Phys

View full text Add to dashboard Cite

show abstract

“…Point detectors such as diodes and thermoluminescent dosimeters are commonly used for these measurements. However, point detectors are sensitive to positioning errors particularly in highly modulated fields [4]. .…”

Section: Introductionmentioning

confidence: 99%